 NEW YORK, May 25, 2021 PRNewswire -- Oramed Pharmaceuticals Inc. Nasdaq: ORMP TASE: ORMP a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, is pleased to provide the following Letter to Shareholders from Chief Executive Officer Nadav Kidron. Dear Shareholders, Im excited to share with you significant milestones we have achieved over the past few months. 